10-Q quarterly report · filed Nov 9, 2026

Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 10-Q Quarterly Report

Short answer

Tonix Pharmaceuticals Holding Corp. (TNXP) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $17M (up 423.8% year over year) with net income of −$53M.

Q3 2026 key financials · XBRL

Revenue
$17M
+423.8% YoY · +27.2% QoQ
Net income
−$53M
−66.6% YoY · −31.5% QoQ
Operating margin
-321.6%
EPS (diluted)
−$2.92
+19.3% YoY · −22.2% QoQ

Source: XBRL data from the Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 10-Q on SEC EDGAR. USD.

Tonix Pharmaceuticals Holding Corp. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $17.2M, up from $3.3M YoY, driven by TONMYA launch
  • TONMYA revenue $15.0M, versus Zembrace SymTouch $1.5M and $2.6M YoY
  • Operating loss $55.4M vs $33.1M; net loss $53.3M vs $32.0M YoY
  • Cash $162.8M; operating cash used $125.6M, financing provided $82.0M through nine months
  • Resources expected to last into early third quarter 2027, with additional funding required; going-concern substantial doubt

Risk Factors

  • New legal risk: DRL’s October 1, 2026 paragraph IV challenge to four TONMYA patents expiring March 14, 2034
  • Patent litigation deadline: 45 days to seek the 30-month FDA approval stay
  • Revenue risk: Generic TONMYA could reduce sales volume and pricing after regulatory exclusivity expires in August 2028
  • New operational risk: AI inaccuracies could misdirect resources or delay development and regulatory submissions
  • New compliance risk: Evolving AI laws may increase compliance costs or limit acceptance of AI-supported analyses

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Tonix Pharmaceuticals Holding Corp. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.